| Abstrakt: |
A recent report discusses the treatment of triple-negative breast cancer (TNBC) in a patient with HIV. The patient received neoadjuvant chemotherapy and pembrolizumab, along with antiretroviral therapy (ART) for HIV. The treatment resulted in a pathological complete response, and the patient experienced limited adverse events. The study suggests that patients with HIV should be included in clinical trials for TNBC and immune checkpoint inhibitors, and that collaboration between breast cancer and HIV clinicians is important for optimal care. [Extracted from the article] |
